Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · technology

Merck KGaA signs up for Evinova's full AI clinical trial suite

30 July 2026 · By · Wire by Fusion42

Published

30 July 2026

Topic

technology

◆ Sectors

Healthtech Infrastructure

◆ Source

Read at firstwordpharma.com →

◆ Verified

Fusion42 · 30 July 2026 · Fusion42 review

Merck KGaA will adopt Evinova's full AI-powered suite for planning and managing clinical trials. This move by the German pharma giant follows similar agreements by Bristol Myers Squibb and Astellas, indicating a trend towards using integrated AI platforms from AstraZeneca's healthtech spin-out to optimise trial design and costs.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.

◆ ◆ The Wire takeaway

The arms race in clinical trial tech is over, and an internal tool from AstraZeneca has won. If you sell software to pharma R&D, one of your biggest potential customers now owns your main competitor.

◆ Coverage

1 source · 30 Jul 2026

◆ Related on Wire

◆ Topics

Healthtech Infrastructurepharma-techai-clinical-trialsdrug-developmentastrazenecamerck-kgaa